1:16 pm

  Local News
  State / National / World
  Opinion / Letters
  Arts / Entertainment
  Submit Event
  Comics / Games
  DJ Designers
  Advertise With Us
  About Us
Allergan to sell Lap-Band unit for $75M in cash
October 30, 2013, 05:00 AM The Associated Press

IRVINE — Cosmetic drug and device maker Allergan Inc. reported better-than-expected earnings Wednesday and announced it is selling its Lap-Band gastric bypass business.

Apollo Endosurgery will give Allergan an upfront payment of $75 million in cash plus a $15 million stake in the company in return for rights to the device, which is a stomach-restricting band used to treat obesity. The deal, which is expected to close this year, also includes up to $20 million in additional payments to Allergan based on various business milestones.

Analysts had high hopes for Allergan’s Lap-Band business, in part because more than a third of American adults are obese. In 2011, Allergan won regulatory approval to expand marketing for Lap-Band to a much wider group of obese patients in the U.S., but demand for the device never met expectations. The stomach-restricting band limits food intake, but can also cause irritation of the esophagus, infection, nausea and vomiting in some cases.

Allergan said its net income rose to $299.8 million, or $1 per share, up from $249.4 million, or 82 cents per share, in the prior year period. When adjusted for one-time events and charges the company would have earned $1.23 per share.

Sales increased 13 percent to $1.56 billion in the quarter. Sales of Botox increased 12.5 percent to $486 million. Last month Allergan won U.S. approval to market the botulin-based injection for a new use to treat crow’s feet, or wrinkles that form on the outside edge of the eyes. The drug is approved for a half-dozen other uses, most famously forehead wrinkles, but also migraines and overactive bladder.

Sales of medical devices, including breast implants, increased 13.4 percent to $198.6 million.

Analysts polled by FactSet expected earnings per share of $1.21 on sales of $1.53 billion.

For the fourth quarter Allergan said it expects earnings per share between $1.31 and $1.33. That’s slightly below the most recent estimate by analysts for $1.35 per share.

Shares of Allergan Inc. fell $1.10, or 1.2 percent, to $92.28 in midday trading. Its shares are up 1 percent from the start of the year.



Tags: allergan, million, share, percent, sales, device,

Other stories from today:


Print this Page Print this Page  |  Bookmark and Share
<< Back
Return To Archives

Daily Journal Quick Poll
Do you agree with Gov. Brown signing The End of Life Option Act, which allows terminally ill patients to end their lives with the help of a doctor?

Yes, it will allow those with terminal conditions to die with dignity
No, doctors are sometimes too hasty in determining someone is terminally ill
Not sure


California governor OKs expansive new equal pay protections
SACRAMENTO — Female workers in California are getting new tools to challenge gender-based wage gap..
Phone scam making the rounds in San Mateo County
The San Mateo County Sheriff's Office is warning residents to beware of a telephone scam involving a..
IMF downgrades forecast for world, emerging market economies
LIMA, Peru — China's slowdown and tumbling commodity prices will push global economic growth this ..
Top general in Afghanistan: US strike on hospital a mistake
WASHINGTON — The deadly American attack on a hospital in northern Afghanistan occurred despite "ri..
More >>  

©2015 San Mateo Daily Journal
San Mateo County advertising